Our own retrospective analyses demonstrate a benefit of racemic ketorolac in ovarian cancer patients and R-ketorolac inhibits Rac1 and Cdc42 GTPases and tumor associated behaviors of human ovarian tumor cells both in vivo and in vitro [20, 124]. This evidence concerns the gene CDC42 and ovarian carcinoma.